Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $3.37 billion. The enterprise value is $3.69 billion.
Important Dates
The next confirmed earnings date is Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 96.20 million shares outstanding. The number of shares has increased by 19.24% in one year.
| Current Share Class | 96.20M |
| Shares Outstanding | 96.20M |
| Shares Change (YoY) | +19.24% |
| Shares Change (QoQ) | +2.26% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 98.18% |
| Float | 92.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.50 |
| Forward PS | 4.58 |
| PB Ratio | 22.11 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 5.58.
| Current Ratio | 2.45 |
| Quick Ratio | 2.10 |
| Debt / Equity | 5.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.47 |
Financial Efficiency
Return on equity (ROE) is -180.44% and return on invested capital (ROIC) is -26.31%.
| Return on Equity (ROE) | -180.44% |
| Return on Assets (ROA) | -21.59% |
| Return on Invested Capital (ROIC) | -26.31% |
| Return on Capital Employed (ROCE) | -49.86% |
| Revenue Per Employee | $471,529 |
| Profits Per Employee | -$411,849 |
| Employee Count | 1,294 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 17.96 |
Taxes
In the past 12 months, RARE has paid $2.54 million in taxes.
| Income Tax | 2.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.52% in the last 52 weeks. The beta is 0.21, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -34.52% |
| 50-Day Moving Average | 31.04 |
| 200-Day Moving Average | 35.18 |
| Relative Strength Index (RSI) | 62.10 |
| Average Volume (20 Days) | 1,277,846 |
Short Selling Information
The latest short interest is 8.69 million, so 9.04% of the outstanding shares have been sold short.
| Short Interest | 8.69M |
| Short Previous Month | 7.65M |
| Short % of Shares Out | 9.04% |
| Short % of Float | 9.37% |
| Short Ratio (days to cover) | 5.08 |
Income Statement
In the last 12 months, RARE had revenue of $610.16 million and -$532.93 million in losses. Loss per share was -$5.52.
| Revenue | 610.16M |
| Gross Profit | -167.80M |
| Operating Income | -505.09M |
| Pretax Income | -530.39M |
| Net Income | -532.93M |
| EBITDA | -469.65M |
| EBIT | -505.09M |
| Loss Per Share | -$5.52 |
Full Income StatementBalance Sheet
The company has $487.59 million in cash and $882.91 million in debt, giving a net cash position of -$343.87 million or -$3.57 per share.
| Cash & Cash Equivalents | 487.59M |
| Total Debt | 882.91M |
| Net Cash | -343.87M |
| Net Cash Per Share | -$3.57 |
| Equity (Book Value) | 158.29M |
| Book Value Per Share | 1.57 |
| Working Capital | 426.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$421.25 million and capital expenditures -$6.06 million, giving a free cash flow of -$427.30 million.
| Operating Cash Flow | -421.25M |
| Capital Expenditures | -6.06M |
| Free Cash Flow | -427.30M |
| FCF Per Share | -$4.44 |
Full Cash Flow StatementMargins
Gross margin is -27.50%, with operating and profit margins of -82.78% and -87.34%.
| Gross Margin | -27.50% |
| Operating Margin | -82.78% |
| Pretax Margin | -86.93% |
| Profit Margin | -87.34% |
| EBITDA Margin | -76.97% |
| EBIT Margin | -82.78% |
| FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.24% |
| Shareholder Yield | -19.24% |
| Earnings Yield | -15.93% |
| FCF Yield | -12.77% |
Dividend DetailsAnalyst Forecast
The average price target for RARE is $87.69, which is 150.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $87.69 |
| Price Target Difference | 150.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 32.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -2.78 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.78 |
| Piotroski F-Score | 4 |
